Fibrinolytic Agents in Thromboembolic Diseases: Historical Perspectives and Approved Indications
Rashedi S, Greason C, Sadeghipour P, Talasaz A, O'Donoghue M, Jimenez D, Monreal M, Anderson C, Elkind M, Kreuziger L, Lang I, Goldhaber S, Konstantinides S, Piazza G, Krumholz H, Braunwald E, Bikdeli B. Fibrinolytic Agents in Thromboembolic Diseases: Historical Perspectives and Approved Indications. Seminars In Thrombosis And Hemostasis 2024, 50: 773-789. PMID: 38428841, DOI: 10.1055/s-0044-1781451.Peer-Reviewed Original ResearchST-segment elevation myocardial infarctionTissue plasminogen activatorFood and Drug AdministrationFibrinolytic agentsThromboembolic diseasePlasminogen activatorFood and Drug Administration approvalArterial thromboembolic eventsElevation myocardial infarctionCentral venous access device occlusionPlasma half-lifeU.S. Food and Drug AdministrationAcute ischemic strokePulmonary embolismThromboembolic eventsHemodynamic compromiseDevice occlusionTreated patientsRecanalize occluded vesselsActive protease plasminDrug AdministrationMyocardial infarctionApproved indicationsOccluded vesselIschemic stroke